208 related articles for article (PubMed ID: 29508897)
21. Pharmacokinetics and Abuse Potential of Asalhydromorphone, a Novel Prodrug of Hydromorphone, After Intranasal Administration in Recreational Drug Users.
Guenther S; Mickle TC; Barrett AC; Smith A; Braeckman R; Kelsh D; Vince B
Pain Med; 2020 Mar; 21(3):511-520. PubMed ID: 30986302
[TBL] [Abstract][Full Text] [Related]
22. Opioid-Induced "Likeability" and "Feeling Good" Are Not Associated With Return Visits to an ED Among Migraine Patients Administered IV Hydromorphone.
Friedman BW; Latev A; Campbell C; White D
Headache; 2018 May; 58(5):750-754. PubMed ID: 29516486
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial.
Chang AK; Bijur PE; Meyer RH; Kenny MK; Solorzano C; Gallagher EJ
Ann Emerg Med; 2006 Aug; 48(2):164-72. PubMed ID: 16857467
[TBL] [Abstract][Full Text] [Related]
24. Trends in and predictors of hydromorphone administration in US emergency departments (2007-2014).
Mazer-Amirshahi M; Ladkany D; Mullins PM; Motov S; Perrone J; Nelson LS; Pines JM
J Opioid Manag; 2018; 14(4):265-272. PubMed ID: 30234923
[TBL] [Abstract][Full Text] [Related]
25. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study.
Lawlor P; Turner K; Hanson J; Bruera E
Pain; 1997 Aug; 72(1-2):79-85. PubMed ID: 9272790
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, open-label, exploratory dose-ranging trial of intranasal hydromorphone for managing acute pain from traumatic injury.
Wermeling DP; Clinch T; Rudy AC; Dreitlein D; Suner S; Lacouture PG
J Pain; 2010 Jan; 11(1):24-31. PubMed ID: 19592310
[TBL] [Abstract][Full Text] [Related]
27. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
Nalamachu SR; Kutch M; Hale ME
J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
29. Effective analgesia with low-dose ketamine and reduced dose hydromorphone in ED patients with severe pain.
Ahern TL; Herring AA; Stone MB; Frazee BW
Am J Emerg Med; 2013 May; 31(5):847-51. PubMed ID: 23602757
[TBL] [Abstract][Full Text] [Related]
30. Opioid-induced Euphoria Among Emergency Department Patients With Acute Severe Pain: An Analysis of Data From a Randomized Trial.
Abril Ochoa L; Naeem F; White DJ; Bijur PE; Friedman BW
Acad Emerg Med; 2020 Nov; 27(11):1100-1105. PubMed ID: 32220099
[TBL] [Abstract][Full Text] [Related]
31. Trends in medical use and abuse of opioid analgesics.
Joranson DE; Ryan KM; Gilson AM; Dahl JL
JAMA; 2000 Apr; 283(13):1710-4. PubMed ID: 10755497
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of hydromorphone in acute and chronic pain.
Quigley C; Wiffen P
J Pain Symptom Manage; 2003 Feb; 25(2):169-78. PubMed ID: 12590032
[TBL] [Abstract][Full Text] [Related]
33. Changes in Provider Prescribing Patterns After Implementation of an Emergency Department Prescription Opioid Policy.
Osborn SR; Yu J; Williams B; Vasilyadis M; Blackmore CC
J Emerg Med; 2017 Apr; 52(4):538-546. PubMed ID: 28111065
[TBL] [Abstract][Full Text] [Related]
34. Randomized clinical trial comparing a patient-driven titration protocol of intravenous hydromorphone with traditional physician-driven management of emergency department patients with acute severe pain.
Chang AK; Bijur PE; Davitt M; Gallagher EJ
Ann Emerg Med; 2009 Oct; 54(4):561-567.e2. PubMed ID: 19560838
[TBL] [Abstract][Full Text] [Related]
35. Morphine or hydromorphone: which should be preferred? A systematic review.
Spénard S; Gélinas C; D Trottier E; Tremblay-Racine F; Kleiber N
Arch Dis Child; 2021 Oct; 106(10):1002-1009. PubMed ID: 33461958
[TBL] [Abstract][Full Text] [Related]
36. Pilot study of human recombinant hyaluronidase-enhanced subcutaneous hydration and opioid administration for sickle cell disease acute pain episodes.
Sandoval M; Coleman P; Govani R; Siddiqui S; Todd KH
J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):10-8. PubMed ID: 23527666
[TBL] [Abstract][Full Text] [Related]
37. The metamorphosis of hydromorphone.
Reisfield GM; Wilson GR
J Opioid Manag; 2005; 1(3):139-45. PubMed ID: 17315417
[TBL] [Abstract][Full Text] [Related]
38. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
39. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain.
Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
J Int Med Res; 2008; 36(2):343-52. PubMed ID: 18380946
[TBL] [Abstract][Full Text] [Related]
40. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.
Carter NJ; Keating GM
CNS Drugs; 2010 Apr; 24(4):337-61. PubMed ID: 20297858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
